Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III

The purpose of this paper is to discuss on the latest progress of the NBP 2005 through selecting significant performance indicators towards the end of policy tenure, which is nurturing 20 global status companies. The research was carried out through qualitative method using verbatim analysis from Fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Baqutayan, Shadiya, Md. Salimun, Husni Alhan
Format: Article
Published: ThinkBiotech LLC 2018
Subjects:
Online Access:http://eprints.utm.my/id/eprint/86316/
http://dx.doi.org/10.5912/jcb818
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.utm.86316
record_format eprints
spelling my.utm.863162020-08-31T13:57:44Z http://eprints.utm.my/id/eprint/86316/ Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III Baqutayan, Shadiya Md. Salimun, Husni Alhan Q Science (General) T Technology (General) The purpose of this paper is to discuss on the latest progress of the NBP 2005 through selecting significant performance indicators towards the end of policy tenure, which is nurturing 20 global status companies. The research was carried out through qualitative method using verbatim analysis from Focus Group Discussion (FGD) with lead implementing agencies, Bioeconomy Corporation and also supported by desktop research from the statistics provided and literature review. Through this research, general performances in NBP Phase II were examined, as they will influence the strategies execution in the Phase III. Hence, researcher was exploring the global companies in the context of NBP in term of definition, grooming programs, potential and existing companies, characteristics, niches, and other relevant information related. The findings of this research indicated that NBP Phase II showed significant achievements while general information on the global companies been obtained, mostly in 3 main biotechnology sectors the namely agriculture, healthcare and industrial biotechnology due to non-disclosure agreement with the companies. Therefore, this research is very useful, it could possibly benefit policy makers in the future on policy planning, and intervention in science, technology, and innovation related policy. Finally, originality value from this research will unlock possibility for future study to conduct quantitative survey on the respective companies and also other international benchmarking indicators. However, the study was only based on the FGD session, documents analysis, and information given from ministries and agencies officers. ThinkBiotech LLC 2018-04 Article PeerReviewed Baqutayan, Shadiya and Md. Salimun, Husni Alhan (2018) Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III. Journal of Commercial Biotechnology, 24 (2). pp. 21-26. ISSN 1462-8732 http://dx.doi.org/10.5912/jcb818 DOI:10.5912/jcb818
institution Universiti Teknologi Malaysia
building UTM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Teknologi Malaysia
content_source UTM Institutional Repository
url_provider http://eprints.utm.my/
topic Q Science (General)
T Technology (General)
spellingShingle Q Science (General)
T Technology (General)
Baqutayan, Shadiya
Md. Salimun, Husni Alhan
Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
description The purpose of this paper is to discuss on the latest progress of the NBP 2005 through selecting significant performance indicators towards the end of policy tenure, which is nurturing 20 global status companies. The research was carried out through qualitative method using verbatim analysis from Focus Group Discussion (FGD) with lead implementing agencies, Bioeconomy Corporation and also supported by desktop research from the statistics provided and literature review. Through this research, general performances in NBP Phase II were examined, as they will influence the strategies execution in the Phase III. Hence, researcher was exploring the global companies in the context of NBP in term of definition, grooming programs, potential and existing companies, characteristics, niches, and other relevant information related. The findings of this research indicated that NBP Phase II showed significant achievements while general information on the global companies been obtained, mostly in 3 main biotechnology sectors the namely agriculture, healthcare and industrial biotechnology due to non-disclosure agreement with the companies. Therefore, this research is very useful, it could possibly benefit policy makers in the future on policy planning, and intervention in science, technology, and innovation related policy. Finally, originality value from this research will unlock possibility for future study to conduct quantitative survey on the respective companies and also other international benchmarking indicators. However, the study was only based on the FGD session, documents analysis, and information given from ministries and agencies officers.
format Article
author Baqutayan, Shadiya
Md. Salimun, Husni Alhan
author_facet Baqutayan, Shadiya
Md. Salimun, Husni Alhan
author_sort Baqutayan, Shadiya
title Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
title_short Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
title_full Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
title_fullStr Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
title_full_unstemmed Evaluation on national biotechnology policy (NBP) 2005: Towards achieving 20 global companies in NBP phase III
title_sort evaluation on national biotechnology policy (nbp) 2005: towards achieving 20 global companies in nbp phase iii
publisher ThinkBiotech LLC
publishDate 2018
url http://eprints.utm.my/id/eprint/86316/
http://dx.doi.org/10.5912/jcb818
_version_ 1677781160576417792
score 13.160551